申请人:Treventis Corporation
公开号:US20150266838A1
公开(公告)日:2015-09-24
In general, among other things, compounds of Formula I are provided:
in which R
11
is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc.; R
13
is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc.; and R
12
and R
14
are each independently hydrogen or alkyl. Methods of treatment are also provided.
一般而言,提供了化合物I的衍
生物,其中R11选自苯甲
氨基、N-甲基苯甲
氨基、
吗啡啶、
硫代
吗啡啶、
吡咯烷等组成的群体;R13选自3-(1-
乙醇-2-基)苯基、3-(1-醇-
2,2,2-三氟乙基-2-基)苯基、2-(1-醇-
2,2,2-三氟乙基-2-基)苯基等组成的群体;R12和R14各自独立地为氢或烷基。同时提供了治疗方法。